Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant pleural mesothelioma].

M Gross-Goupil1, P Ruffié

  • 1Institut Gustave-Roussy, rue Camille-Desmoulins, 94805 Villejuif.

Bulletin Du Cancer
|December 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors for RNA integrity in fresh-frozen renal cancer samples from routine practice (UroCCR 9).

The French journal of urology·2026
Same author

Segmental 3D image-guided robot-assisted partial nephrectomy (3D-IGRAPN) in selected cases of localized renal urothelial carcinoma.

World journal of urology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.

Cancer immunology, immunotherapy : CII·2022
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Malignant pleural mesothelioma, a rare asbestos-linked cancer, presents diagnostic challenges. Current treatments offer limited survival benefits, highlighting the need for clinical trial participation.

Area of Science:

  • Oncology
  • Pathology
  • Radiology

Context:

  • Malignant pleural mesothelioma is a rare neoplasm.
  • Asbestos exposure is the primary risk factor, implicated in 72-95% of cases.
  • Diagnosis is often delayed due to nonspecific symptoms like chronic pleural effusion and dyspnea.

Purpose:

  • To review the diagnostic challenges, classification systems, prognostic factors, and current therapeutic strategies for malignant pleural mesothelioma.
  • To emphasize the limited efficacy of existing treatments and the importance of clinical trials.

Summary:

  • Histological diagnosis relies on thoracoscopic biopsy, supported by histochemical and immunohistochemical analyses.
  • Tumor staging utilizes thoracic CT scans and classification systems like IMIG.

Related Experiment Videos

  • Prognostic indicators include disease stage, histologic type, and patient performance status.

    • Impact:

    • Current therapeutic options including surgery, chemotherapy, and radiotherapy have not significantly improved survival rates.
    • Radical surgery is reserved for early-stage disease.
    • Chemotherapy shows limited response rates, and radiotherapy is constrained by toxicity and proximity to vital organs, underscoring the need for novel therapeutic approaches within clinical trials.